Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab vs Nivolumab + Ipilimumab in GIST
NCT02880020Phase 2Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Dec 2016
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in gastrointestinal stromal tumor (GIST), sponsored by UCLA Jonsson Comprehensive Cancer Center. Started Dec 2016; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT02880020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02880020.